Myocardial hypertrophy is characterized by an increase of cardiomyocyte protein synthesis and cell volume, and it is crucial for the transition from adaptive to maladaptive cardiac function with the progression to irreversible changes. Although some extent of cardiac hypertrophy serves to reduce wall stress and compensate for an increased load on the myocardium,^[@R1]^ the effect of sustained prohypertrophic signaling on cardiomyocytes is detrimental and makes a major contribution to eventual progression to heart failure.^[@R2],[@R3]^ Clinical and experimental studies have shown that the withdrawal of pressure overload, such as aortic debanding in animals and aortic valve replacement in patients with aortic stenosis, leads to the regression of myocardial hypertrophy^[@R4]--[@R6]^ and various beneficial molecular changes.^[@R4],[@R7]^ It has been reported that intermittent systolic overload promotes the improvement of myocardial performance in adult animals,^[@R8]^ producing both a mild hypertrophic response and a favorable fetal gene expression profile.^[@R9]^ However, it is completely unknown whether the removal of short-term or long-term pressure overload renders the heart resistant to subsequent prolonged prohypertrophic stimulation.
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The phenomenon of ischemic preconditioning whereby brief episodes of ischemia increase cardiac resistance to subsequent prolonged ischemia has received considerable attention since it was first reported by Murry et al in 1986.^[@R10]^ In addition to ischemia, pretreatment with hypoxia, hyperbaric oxygen, or certain drugs can induce this protective effect of preconditioning.^[@R11]--[@R15]^ Similarly, it would be plausible that short-term hypertrophic stimulation makes the heart resistant to subsequent hypertrophic stress. Indeed, an animal study has shown that a short-term antihypertensive therapy has a prolonged antihypertrophic effect on the myocardium and can protect the heart.^[@R16]^ In addition, it was reported that relief from cardiac pressure overload significantly alters the gene expression profile, including some of the known antihypertrophic genes.^[@R17]^ Thus, it appears that antihypertensive therapy or the removal of prohypertrophic stimulation creates an antihypertrophic memory, but it is unclear how long such an effect persists.

It is well known that a similar level of pressure overload (eg, hypertension) can cause different degrees of myocardial hypertrophy. Also, the prevalence of myocardial hypertrophy is \<50% in patients with essential hypertension,^[@R18]^ suggesting that factors that resist prohypertrophic stimulation exist in many patients. Experimental studies have demonstrated that some factors can prevent cardiac hypertrophy independent of an antihypertensive effect,^[@R19]^ but it remains unclear how to induce such antihypertrophic factors for therapeutic purposes. Based on the points mentioned here, we propose a new concept termed myocardial hypertrophic preconditioning. Our hypothesis is that short-term hypertrophic stimulation can render the heart resistant to subsequent hypertrophic stress and slow the progression to heart failure. In this study, we attempted to demonstrate the phenomenon of hypertrophic preconditioning and investigate the mechanisms involved.

Methods
=======

All procedures were performed in accordance with our Institutional Guidelines for Animal Research and the investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85--23, revised in 1996).

Cell Culture
------------

The neonatal rats were euthanized by 2% isoflurane inhalation and cervical dislocation. The isolation and culturing of neonatal rat ventricular cardiomyocytes (NRVCs) and fibroblasts were performed as described previously.^[@R20],[@R21]^ Three groups were designed: (1) the norepinephrine (NE) group: 1 μmol/L NE (dissolved in Dulbecco's modification of Eagle's medium) for 48 hours; (2) the preconditioning (Pre)+NE group: after stimulation for 12 hours, NE was removed for another 12 hours, and then NE was added again to stimulate for 48 hours; (3) the control group: Dulbecco's modification of Eagle's medium treatment for 48 hours (Figure [1](#F1){ref-type="fig"}A). Cardiomyocytes were harvested and analyzed for cell surface and expression of atrial natriuretic peptide (ANP) and β-myosin heavy chains (β-MHCs).

![Experimental protocols for the detection of myocardial hypertrophic preconditioning (Pre). **A**, Experiment 1: Pre in cultured cardiomyocytes: norepinephrine (NE)-induced myocardial hypertrophy. **B**, Experiment 2: Hypertrophic preconditioning in phenylephrine (PE) infusion--induced myocardial hypertrophy in mice. **C**, Experiment 3: Short-term effect of Pre on myocardial hypertrophy in mice with transverse aortic constriction (TAC). **D**, Experiment 4: Long-term effect of Pre on myocardial hypertrophy and heart failure in mice with TAC. DMEM indicates Dulbecco's modification of Eagle's medium.](cir-131-1506-g001){#F1}

The effects of recombinant murine S100A8 (also called myeloid-related protein \[MRP\] 8, Abcam), S100A9 (mouse MRP-14, Abcam) on NRVCs were examined. Five groups were designed as follows: (1) NE group: 1 μmol/L NE treatment for 48 hours; (2) NE+S100A8 group: treatment with 1 μmol/L NE and S100A8 (1 μg/mL) for 48 hours; (3) NE+S100A9 group: treatment with 1 μmol/L NE and S100A9 (1 μg/mL) for 48 hours; (4) NE+S100A8/A9 group: treatment with 1 μmol/L NE and S100A8/A9 (1 μg/mL) for 48 hours; and (5) control group: treatment with Dulbecco's modification of Eagle's medium for 48 hours. Cell surface area and the expression of ANP, β-MHC, calcineurin, and nuclear factor of activated T cells (NFAT) in cardiomyocytes, procollagen I, and procollagen III mRNA in fibroblasts were analyzed.

Animal Models and Experimental Protocols
----------------------------------------

### Creation of Drug-Induced Myocardial Hypertrophy Model

C57BL/6 male mice (8--10 weeks, 20--25 g) were anesthetized with a mixture of xylazine (5 mg/kg IP) and ketamine (100 mg/kg IP). After anesthesia, the mice were subjected to subcutaneous pump implantation in the back with an osmotic minipump (Alzet) filled with phenylephrine (PE, 30 mg·kg^--1^·d^--1^, dissolved in 0.5 mmol/L ascorbic acid) or vehicle (0.5 mmol/L ascorbic acid), the incision was closed with 2 wound clips. For the preconditiong group, changing from PE to vehicle or vice versa was performed by removing the old pump and implanting a new one. Animals in the control group and PE group received a similar procedure for replacing of pump (filled with vehicle alone) during the preconditioning time window. These mice were euthanized by overdose anesthesia (pentobarbital sodium 150 mg/kg IP) and cervical dislocation at 4 to 8 days to obtain heart and calculate heart weight/body weight ratio. The mice were divided into 3 groups, with 6 to 7 mice in each group, as follows: (1) PE group: PE infusion (in ascorbic acid) for 4 days; (2) Pre+PE group: PE infusion for 1 day and then stop for 1 day, followed by PE infusion for 2 days and stop for 2 days, and finally recovered PE infusion for 4 days; (3) control group: ascorbic acid infusion for 4 days (Figure [1](#F1){ref-type="fig"}B).

### Transverse Aortic Constriction Model

C57BL/6 male mice (8--10 weeks, 18--25 g) were subjected to transverse aortic constriction (TAC) or debanding or sham operation as described elsewhere.^[@R4],[@R22]^ In brief, after a left-sided thoracotomy in the second intercostal space, a 7-0 silk ligature was tied around the transverse aorta and a 27-gauge blunted needle that was subsequently removed (Movie I in the online-only Data Supplement), whereas, in sham-operated animals, the ligature was tied loosely around the aorta. At the indicated time, a debanding operation was performed by carefully removing the ligature (Movie II in the online-only Data Supplement). To avoid possible confounding effects of the repeated surgical injury, sham or nonpreconditioning animals were also subjected to a similar open-chest operation. Two experimental protocols were designed for this model (Figure [1](#F1){ref-type="fig"}C): (1) short-term effect of hypertrophic preconditioning. Three groups were included: the sham group and the TAC group, observation for 7 days; and the Pre+TAC group, debanding the aorta after 3 days of TAC (TAC for 3 days in mice is sufficient to induce significant cardiac hypertrophy; see Figure I in the online-only Data Supplement), and banded again 4 days later followed by observation for 7 days. (2) Long-term effect of preconditioning (Figure [1](#F1){ref-type="fig"}D). Four groups were designed: the sham group and the TAC group, observation for 6 weeks; the Pre1+TAC group, debanding the aorta after 3 days of TAC, and banded again 4 days later followed by observation for 6 weeks; and the Pre2+TAC group, debanding the aorta after 1 week of TAC, and banded again 1 week later followed by observation for 6 weeks. These mice and sham-operated mice were euthanized by overdose anesthesia (pentobarbital sodium 150 mg/kg IP) at 1 to 8 weeks after the operation. Preconditioning with TAC for 3 days or 1 week induced significant myocardial hypertrophy (Figure I in the online-only Data Supplement), which may be assured as compensatory hypertrophy.

Left ventricular (LV) hemodynamics was evaluated by using a Millar catheter and Blood Pressure Module software in some mice before euthanization as we reported elsewhere.^[@R23]^

Echocardiography, Western Blot, Polymerase Chain Reaction Immunofluorescence, Construction of Lentivirus Carrying Overexpressed or Short-Hairpin RNA for S100A8 or A9, Cell Viability Assay, and Histological Examinations
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

See details in Materials in the online-only Data Supplement. Infection efficiency and the expression levels of targeted genes S100A8 or A9 are shown in Figure II in the online-only Data Supplement. Sequences of primers for routine polymerase chain reaction, quantitative real-time polymerase chain reaction, and synthesis of S100A8/A9 cDNA are shown in Tables I through III in the online-only Data Supplement, respectively.

Statistical Analysis
--------------------

Quantitative data are expressed as mean±standard error of the mean. For all statistical tests, multiple comparisons were performed by 1-way analysis of variance with the Bonferroni multiple comparison test (SPSS 16.0). The least-squares method was used to assess linear correlations between selected variables. The overall survival of TAC mice for 10 days was evaluated by using Kaplan-Meier survival analysis, and groups were compared by the log-rank test. *P* values of \<0.05 were considered to be statistically significant.

Results
=======

Antihypertrophic Effect of Hypertrophic Preconditioning In Vitro
----------------------------------------------------------------

Using our database of TAC or sham mice, we analyzed cardiac hypertrophy, pulmonary congestion, and left ventricle hemodynamics in 74 C57 male mice subjected to either TAC or sham operation for 4 to 8 weeks (Figure IIIA through IIIC in the online-only Data Supplement), and found that some animals displayed antihypertrophic phenomena even under a similar high-pressure overload, suggesting that antihypertrophic factors are inducible to render the heart resistant to the persistent pressure overload. Then we used hypertrophic Pre treatments that were designed with modification according to the ischemic preconditioning protocol to test whether hypertrophic preconditioning affords cardiac protection. In the cultured cardiomyocytes, we noted that NRVCs showed a significant increase of cell size in response to NE stimulation, whereas preconditioning treatment suppressed this increase (Figure [2](#F2){ref-type="fig"}A). Meanwhile, the increased expression of fetal genes (ANP and β-MHC) in the preconditioning group was significantly attenuated (Figure [2](#F2){ref-type="fig"}B). These results indicate that hypertrophic preconditioning renders an antihypertrophic role in cardiomyocytes.

![Effect of hypertrophic preconditioning (Pre) on myocardial hypertrophy in cultured cardiomyocytes and phenylephrine (PE) infusion mouse model. **A**, Representative confocal microscopic images of cultured neonatal rat cardiomyocytes stained with α-actin plus DAPI staining of the nucleus and semiquantitative analysis of cardiomyocyte area in response to NE stimulation with/without preconditioning or vehicle treatment. \**P*\<0.01 vs NE. **B**, Results of PCR for ANP and β-MHC in cultured cardiomyocytes. ^\#^*P*\<0.01, \**P*\<0.05 vs NE. **C**, Effect of PE infusion-induced preconditioning on heart weight/body weight ratio (HW/BW), n=7, 7, and 6 in vehicle, PE, and Pre group, respectively. **D**, PCR results of myocardial ANP and β-MHC, n=5 in each group, ^\#^*P*\<0.01, \**P*\<0.05 vs PE. **E**, Representative pictures of H&E (**Top**) and Masson (**Bottom**) stained myocardial tissues. Scale bar, 20 μm. ANP indicates atrial natriuretic peptide; DAPI, 4′,6-diamidino-2-phenylindole; H&E, hematoxylin and eosin; β-MHC, β-myosin heavy chain; NE, norepinephrine; and PCR, polymerase chain reaction.](cir-131-1506-g002){#F2}

Antihypertrophic Effect of Hypertrophic Preconditioning In Vivo
---------------------------------------------------------------

In mice with induction of myocardial hypertrophy by persistent infusion of PE for a short term of 4 days, the heart weight/body weight ratio and expression levels of hypertrophic markers ANP and β-MHC were significantly smaller in the preconditioning group than in the PE group (Figure [2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D, *P*\<0.05), but no detectable difference was noted on myocardial fibrosis assessed with Masson trichrome staining (Figure [2](#F2){ref-type="fig"}E).

Using mouse TAC model, we noted that 1 week after TAC, the heart weight/body weight ratio was smaller in the preconditioning group than in the TAC group (5.35±0.17 mg/g versus 5.99±0.22 mg/g, *P*=0.014; Figure [3](#F3){ref-type="fig"}A). Our previous study showed that TAC mice may die of acute heart failure^[@R23]^; thus, we here examined whether hypertrophic preconditioning exerts influence on survival. As shown in Figure [3](#F3){ref-type="fig"}B, the survival rate for the first 10 days after TAC was significantly lower in mice receiving preconditioning for 3 days than in mice with TAC alone, suggesting the acute cardioprotection of hypertrophic preconditioning. We further investigated the long-term effect of hypertrophic preconditioning on hypertrophy. At 6 weeks after TAC, heart weight/body weight ratio was significantly smaller in the 2 preconditioning groups than in the TAC group (7.16±0.33 mg/g for TAC, 5.32±0.14 mg/g for Pre1+TAC, and 5.43±0.11 mg/g for Pre2+TAC, *P*\<0.01; Figure [3](#F3){ref-type="fig"}C and [3](#F3){ref-type="fig"}D), whereas the cardiomyocyte area was significantly smaller in the Pre1+TAC and Pre2+TAC groups than in the TAC group (Figure [3](#F3){ref-type="fig"}E). In addition, the increase of fetal gene expression (ANP and β-MHC) was significantly attenuated in the 2 preconditioning groups (Figure [3](#F3){ref-type="fig"}F). The above findings indicate that hypertrophic preconditioning in vivo improves acute-phase survival and attenuates myocardial hypertrophy.

![Effect of hypertrophic preconditioning (Pre) on myocardial hypertrophy. **A**, HW/BW at 1 week after transverse aortic constriction (TAC) or sham operation, n=6 in each group. **B**, Survival rate in the first 10 days after TAC in TAC group and Pre1+TAC group. **C**, Representative pictures of whole heart at 6 weeks after TAC or sham operation, scale bar=2 mm. **D**, HW/BW at 6 weeks after TAC or sham operation, n=6 or 7 in each group. **E**, Cardiomyocyte cross area in different groups (sham %) at 6 weeks after TAC or sham operation. Scale bar, 50 μm. **F**, Semiquantitative analysis of myocardial ANP and β-MHC at 6 weeks after TAC or sham operation, n=4 in each group. ^\#^*P*\<0.01, \**P*\<0.05 vs PE or TAC. (Protocols for Pre1 and Pre2 are shown in Figure [1](#F1){ref-type="fig"}D). ANP indicates atrial natriuretic peptide; β-MHC, β-myosin heavy chain; HW/BW, heart weight/body weight ratio; and PE, phenylephrine.](cir-131-1506-g003){#F3}

Hypertrophic Preconditioning Slows Progression of Cardiac Remodeling
--------------------------------------------------------------------

In TAC mice, serial echocardiography showed a time-dependent increase of LV end-diastolic dimension and LV end-systolic dimension (Figure [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B), and of diastolic and systolic LV wall thickness (Figure [4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D), as well, whereas LV fractional shortening decreased over time (Figure [4](#F4){ref-type="fig"}E). In contrast, hypertrophic preconditioning significantly slowed the increase of LV wall thickness (Figure [4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D), the enlargement of LV dimensions (Figure [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B), and the decline of LV fractional shortening (Figure [4](#F4){ref-type="fig"}E). No significant differences were noted between the 2 preconditioning groups (Figure [4](#F4){ref-type="fig"}).

![Effect of hypertrophic preconditioning (P) on cardiac remodeling after transverse aortic constriction (TAC or T) over time. **A**, Left ventricular end-diastolic dimension (LVEDd). **B**, Left ventricular end-systolic dimension (LVESd). **C**, Left ventricular diastolic posterior wall thickness (Pwd). **D**, Left ventricular systolic posterior wall thickness (Pws). **E**, Left ventricular fractional shortening (LVFS). \**P*\<0.05, ^\#^*P*\<0.01 vs TAC group, ^§^*P*\<0.05 vs Sham, n=7 per group. Protocols for P1 and P2 are shown in Figure [1](#F1){ref-type="fig"}D.](cir-131-1506-g004){#F4}

Hypertrophic Preconditioning Improves the Pathophysiology of Heart Failure
--------------------------------------------------------------------------

TAC induced congestive heart failure (HF) with an increase of the LW/BW. Six weeks after TAC, the LW/BW was markedly smaller in the Pre1+TAC and Pre2+TAC groups than in the TAC group (9.88±1.00 mg/g for TAC, 5.98±0.12 mg/g for Pre1+TAC (*P*=0.008), and 6.15±0.11 for Pre2+TAC \[*P*=0.046\]; Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B). In addition, histological examination showed that both myocardial fibrosis and perivascular fibrosis were significantly attenuated in both preconditioning groups in comparison with the TAC group (Figure [5](#F5){ref-type="fig"}C through [5](#F5){ref-type="fig"}E). Echocardiographic LV dimensions (Figure [5](#F5){ref-type="fig"}F) were smaller, LV fractional shortening was larger (Figure [5](#F5){ref-type="fig"}G), LV end-diastolic pressure was lower (Figure [5](#F5){ref-type="fig"}H), and LV contractility (Figure [5](#F5){ref-type="fig"}I) was higher in the preconditioning groups than in TAC alone group (all *P*\<0.05). No significant differences were noted between them on LV posterior wall thickness (LV cavity enlargement in TAC group would decrease wall thickness), LV systolic pressure (suggesting similar pressure overload), heart rate, and LV pressure change rate (Figure IV in the online-only Data Supplement). These findings indicated that hypertrophic preconditioning has an inhibitory effect on cardiac hypertrophy and HF. We subsequently investigated the possible mechanisms involved.

![Effects of hypertrophic preconditioning (Pre or P) on cardiac function and fibrosis. **A**, Representative macroscopic appearance of the lungs in each group. Scale bar, 2 mm. **B**, Lung weight/body weight (LW/BW) ratio at 6 weeks after TAC, n=6 or 7 in each group. **C**, Representative Masson-stain pictures of perivascular and myocardial fibrosis from each group. Scale bar, 50 μm. **D**, Quantitative analysis of perivascular fibrosis, n=4 per group. **E**, Quantitative analysis of myocardial fibrosis, n=4 per group. For **B**, **D** and **E**, \**P*\<0.05, ^\#^*P*\<0.01 vs TAC group. Before euthanization, left ventricular dimensions (LVD; **F**) and LV fractional shortening (LVFS; **G**) were measured by using echocardiography, whereas LV end-diastolic pressure (LVEDP; **H**) and LV contractility (**I**) were measured by using a Millar catheter. For **F** through **I**, n=5 to 7, \**P*\<0.05, ^\#^*P*\<0.01 vs TAC group. LV indicates left ventricular; LVEDd, left ventricular end-diastolic dimension; LVESd, left ventricular end-systolic dimension; and TAC, transverse aortic constriction.](cir-131-1506-g005){#F5}

Upregulation of S100A8/A9 After Withdrawal of Prohypertrophic Stimulation
-------------------------------------------------------------------------

S100A9 was reported to be one of the genes that is specifically induced during the regression of cardiac hypertrophy,^[@R17]^ so we examined the expression of S100A8 and S100A9 after the removal of stimulation. We found that expression of S100A8 and S100A9 mRNA and their corresponding proteins in cultured NRVCs was similar between control cells and NE-stimulated cells, but was markedly upregulated at 12 hours after the withdrawal of NE (Figure [6](#F6){ref-type="fig"}A and [6](#F6){ref-type="fig"}B). Consistent with these findings, myocardial gene and protein expression of S100A8 and S100A9 was also significantly increased in mice 1 day after debanding that had been preceded by 3 days or 1 week of TAC (Figure [6](#F6){ref-type="fig"}C through [6](#F6){ref-type="fig"}E).

![S100A8/A9 mRNA and protein expression after the removal of prohypertrophic stimulation. **A**, Real-time quantitative polymerase chain reaction (PCR) for expression of S100A8 and S100A9 in cultured neonatal rat ventricular cardiomyocytes (NRVCs). **B**, Western blot analysis of S100A8 and S100A9 expression in cultured NRVCs. **C**, Real-time quantitative PCR for myocardial expression of S100A8 and S100A9 in mice. For **A** through **C**, \**P*\<0.05 vs norepinephrine (NE) or transverse aortic constriction (TAC) group, n=3 to 5 per group. Insets in **A** and **C** are amplification curves of real-time PCR. **D** and **E**, Western blot analysis of myocardial S100A8 (**D**) and S100A9 (**E**) expression in mice in response to TAC (T) or sham, or debanding or reimposition of pressure overload. \**P*\<0.05, ^\#^*P*\<0.01 vs TAC 1w group, n=5 in each group. D indicates debanding; T, TAC; T/D/T1w, TAC for 1 week, then debanding for 1 week followed by re-TAC for 1 week; and T/D/T6w, TAC for 1 week, then debanding for 1 week followed by re-TAC for 6 weeks.](cir-131-1506-g006){#F6}

We further checked how long the upregulation of S100A8/A9 would persist after reimposition of pressure overload followed by debanding for 4 days. As shown in Figure [6](#F6){ref-type="fig"}D and [6](#F6){ref-type="fig"}E, S100A8 or A9 was significantly increased in response to debanding, which was continued until 1 week and 6 weeks after reimposition of hypertrophic stimuli.

Recombinant S100A8/A9 Attenuates Hypertrophy and Fibrosis In Vitro
------------------------------------------------------------------

We further investigated whether recombinant S100A8 and S100A9 proteins had antihypertrophic effects in cultured NRVCs and fibroblasts. As shown in Figure [7](#F7){ref-type="fig"}A and [7](#F7){ref-type="fig"}B, the treatment with either S100A8 or S100A9 (or both proteins) significantly suppressed the NE-induced increase in the surface area of cardiomyocytes. In comparison with control cells, exposure to NE for 48 hours increased the expression of ANP and β-MHC mRNA in NRVCs (Figure [7](#F7){ref-type="fig"}C and [7](#F7){ref-type="fig"}D), and the expression of procollagen I and III mRNA in fibroblasts, as well (Figure [7](#F7){ref-type="fig"}E), whereas treatment with S100A8, S100A9, or both of these proteins prevented such changes (Figure [7](#F7){ref-type="fig"}C through E). These findings suggested that S100A8 and S100A9 could attenuate NE-induced hypertrophy and fibrosis in cultured cardiac cells.

![Effect of S100A8/A9 treatment on myocyte hypertrophy in cultured neonatal rat ventricular cardiomyocytes (NRVCs) and fibroblasts. **A**, Cardiomyocytes stained with α-actin and DAPI. **B**, Semiquantitative analysis of cardiomyocyte area. **C**, PCR for ANP and β-MHC expression in NRVCs. Real-time quantitative PCR for expression of ANP and β-MHC in NRVCs (**D**) and for expression of procollagen I and procollagen III in fibroblasts (**E**). **F**, Representative Western blot of calcineurin in NRVCs treated with recombinant S100A8/A9. **G**, Detection of nuclear factor of activated T cells (NFAT) in subcellular fractions by Western blotting. Histone 3 was the loading control for nuclear extracts, and β-actin was the loading control for cytosolic extracts. **H**, Semiquantitation of calcineurin and NFATc3 Western blotting results in NRVCs (n = nuclear, c = cytosolic). \**P*\<0.05, \#*P*\<0.01 vs NE group, experiments were repeated for 3 to 5 times. ANP indicates atrial natriuretic peptide; DAPI, 4′,6-diamidino-2-phenylindole; β-MHC, β-myosin heavy chain; NE, norepinephrine; and PCR, polymerase chain reaction; A8, S100A8; A9, S100A9; A8/9, S100A8/9.](cir-131-1506-g007){#F7}

The exposure of NRVCs to NE resulted in increased expression of calcineurin, but this was abrogated by the treatment with either S100A8 or S100A9, or both of these proteins (Figure [7](#F7){ref-type="fig"}F and [7](#F7){ref-type="fig"}H). When the subcellular localization of NFATc3 was assessed by Western blotting, it was primarily localized in the cytoplasm of control cells and underwent translocation to the nucleus in response to NE stimulation, whereas treatment with S100A8 or S100A9, or both of these proteins, inhibited NE-induced nuclear translocation of NFATc3 (Figure [7](#F7){ref-type="fig"}G and [7](#F7){ref-type="fig"}H).

Silencing of S100A8/A9 Attenuates the Antihypertrophic Effects of Hypertrophic Preconditioning
----------------------------------------------------------------------------------------------

The aforementioned results suggest the important role of S100A8/A9 in myocardial hypertrophy. We then used approaches for gain and loss of function to further address this issue. Infection of cardiomyocytes with lentivirus-S100A8 or A9 upregulated S100A8 or A9 by \>200-fold (Figure II in the online-only Data Supplement), which was much higher than the upregulation amplitude in response to debanding (about 6-fold).^[@R17]^ The cell viability test showed that high-dose overexpression of endogenous S100A8 or A9 and a high dose of exogenous S100A8 or A9 increased cardiomyocyte death (Figure V in the online-only Data Supplement), suggesting that the role of S100A8/A9 is dose dependent. Accordingly, we chose the S100A8/A9-silencing approach. Lentivirus (Lv) carrying short-hairpin (Sh) RNA for S100A8/A9 led to a significant silencing effect (Figure [8](#F8){ref-type="fig"}A). In comparison with the preconditioning group, both Lv-Sh-S100A8 and A9 significantly reduced the hypertrophic preconditioning effects manifested by an increase of cardiomyocyte cell surface area (Figure [8](#F8){ref-type="fig"}B), the upregulation of ANP and β-MHC in cardiomyocytes (Figure [8](#F8){ref-type="fig"}C), and the upregulation of procollagens in fibroblasts (Figure [8](#F8){ref-type="fig"}D), increase of calcineurin protein levels (Figure [8](#F8){ref-type="fig"}E), and nuclear translocation of NFAT3 (Figure [8](#F8){ref-type="fig"}F). In cardiomyocytes infected with both Lv-Sh-S100A8 and A9, a low dose of exogenous S100A8 or A9 still significantly inhibited NE-induced upregulation of calcineurin protein (Figure [8](#F8){ref-type="fig"}G), suggesting that exogenous S100A8 or A9 can work as nonheterodimer.

![Silencing of S100A8/A9 antagonizes the effect of hypertrophic preconditioning in neonatal rat ventricular cardiomyocytes (NRVCs) and fibroblasts. S100A8 and S100A9 were knockdown by using short hairpin of RNA for S100A8 (ShA8) and S100A9 (ShA9) and then constructed into lentivirus. **A**, Silencing effect of ShA8 and ShA9. \**P*\<0.05 vs vector, n=3. **B**, Representative pictures of cardiomyocytes stained with α-actin and DAPI and semiquantitative analysis of cardiomyocyte area. Real-time quantitative PCR for expression of ANP and β-MHC in NRVCs (**C**) and for expression of procollagen I and procollagen III in fibroblasts (**D**). **E**, Western blot analysis of calcineurin expression in cardiomyocytes. \**P*\<0.05 vs P+NE group. **F**, Western blot analysis of nuclear factor of activated T cells (NFAT) in subcellular fractions by Western blotting in cardiomyocytes. Histone 3 and β-actin were the loading control for nuclear (n) extracts and cytosolic (c) extracts, respectively. \**P*\<0.05 vs P+NE group. **G**, Western blotting of calcineurin in cardiomyocytes with S100A8/A9 silencing and NE stimulation (1 μmol/L) in the presence/absence of exogenous S100A8 or S100A9 (1 μg/mL). \**P*\<0.05 vs ShA8/9+NE group. All experiments were repeated 3 to 5 times. ShA8/9 = short hairpin RNA of S100A8/9, multiplicity of infection (MOI)=5 for ShA8 or ShA9. ANP indicates atrial natriuretic peptide; β-MHC, β-myosin heavy chain; NE, norepinephrine; P, preconditioning; and PCR, polymerase chain reaction.](cir-131-1506-g008){#F8}

Discussion
==========

This study provided evidence for a new concept termed myocardial hypertrophic preconditioning. We demonstrated that preconditioning by prohypertrophic factors increases the resistance of the heart to subsequent hypertrophic stress and delays the progression from hypertrophy to HF, indicating the existence of the hypertrophic preconditioning phenomenon. We further showed that upregulation of S100A8/A9 following removal of transient hypertrophic stimulus contributes to the antihypertrophic and anti-HF effect of hypertrophic preconditioning, at least in part by suppressing the calcineurin/NFAT pathway.

Cardiac protection by hypertrophic preconditioning has already been reported in the setting of congenital heart disease. In patients with transposition of the great vessels, the LV does not develop properly because it is pumping against low resistance and needs to be strengthened by applying a pulmonary artery band in preparation for corrective surgery.^[@R24]--[@R26]^ Traditional banding procedures quickly reach the target level of stenosis for ventricular retraining, but cause the abrupt onset of fixed systolic overload that can result in LV failure.^[@R24],[@R26]^ Experimental studies have shown that myocardial edema and necrosis occur in hearts with abrupt systolic overload, usually followed by the development of ventricular failure.^[@R23],[@R27]^ In contrast, Sekarski et al demonstrated that ventricular retraining with an adjustable banding device (the target stenosis was gradually reached by the telemetric control system) led to better survival.^[@R26]^ In addition, Miana et al^[@R8]^ reported that intermittent systolic overload by pulmonary banding promoted better myocardial performance in goats, mimicking the physiological hypertrophy achieved by exercise in athletes. These results support our finding that hypertrophic preconditioning improves HF.

In patients with aortic stenosis, the regression of cardiac hypertrophy occurs after aortic valve replacement.^[@R28],[@R29]^ Mechanical unloading can cause the regression of hypertrophy and functional improvement,^[@R30]--[@R32]^ during which process certain genes may be specifically upregulated to either block hypertrophic signaling pathways or trigger atrophic signaling pathways.^[@R7],[@R17]^ Yang et al^[@R7]^ identified a set of genes specifically induced during the regression of hypertrophy, and confirmed that eyes absent 2 homolog (eya2) blocks the development of cardiomyocyte hypertrophy. Among those genes induced during the regression process, S100A9 was upregulated by ≈6-fold, but its role in myocardial hypertrophy and HF remains elusive. S100A8 (calgranulin A or migration inhibitory factor--related protein 8 \[MRP-8\]) and its binding partner S100A9 (calgranulin B, or MRP-14) are members of the S100 calcium-binding family of proteins, which have anti-inflammatory and immunoregulatory actions.^[@R33]--[@R35]^ Although the expression of both S100A8 and S100A9 was reported to be increased in acute coronary syndromes,^[@R36]^ atherosclerosis,^[@R37],[@R38]^ and endotoxin-induced cardiac dysfunction,^[@R39]^ their exact roles have not been clarified. However, cardiac overexpression of S100A8 and S100A9 was reported to decrease calcium flux,^[@R39]^ suggesting that these genes may exert an antihypertrophic effect. In the present study, we demonstrated that treatment with S100A8 and S100A9 inhibited NE-induced cardiomyocyte hypertrophy. Fibrosis is well known to play a critical role in chronic HF. Degradation and accumulation of extracellular matrix are important in the process of LV remodeling, and it has been proposed that matrix metalloproteinases can be used as markers of inflammation and fibrosis.^[@R40]^ In agreement with a recent report^[@R41]^ that stimulation of chondrocytes with S100A8 and S100A9 caused marked downregulation of type II collagen, we found that treatment with S100A8 and S100A9 downregulated procollagens I and III in cultured fibroblasts receiving NE stimulation, which may be a potential mechanism for slowing the progression of HF by hypertrophic Pre.

Although S100A8/S100A9 are generally viewed as proinflammatory, accumulated evidence suggests that S100A8/A9 can exert pleiotropic roles such as anti-inflammatory and immune regulatory actions in a context-dependent and cell type--specific manner. S100A8 is essential for life because S100A8 knockout mice died during embryonic development.^[@R42]^ It seems that their doses, posttranslational modifications, their binding to the different receptors may lead to distinct functional outcomes. Our supplementary experiments also showed that a high dose (10 μg/mL) or overexpression of S100A8/A9 reduced the viability of cardiomyocytes, whereas a low dose (1 μg/mL) exerted no harmful effect, which is in agreement with previous studies showing that a high dose of S100A8 (30 μg/mouse) aggravates lung injury,^[@R43]^ whereas its low dose (10 μg/mouse) protected from acute lung injury.^[@R44]^ Several lines of recent evidence support the idea that S100A8/A9 may exert cell-protective roles. S100A8 was reported to promote angiogenesis,^[@R45]^ which should be beneficial for the improvement of cardiac dysfunction by alleviating the relative ischemia of hypertrophied myocardium. S100A9 knockout mice increased renal damage and fibrosis in response to ischemia/reperfusion,^[@R46]^ and S100A8/A9 also showed the ability to inhibit the cell growth of cancer,^[@R47]^ lending support to our finding that hypertrophic Pre attenuates myocardial fibrosis and myocyte hypertrophy, in part, by the upregulation of S100A9. Similar to ischemia preconditioning, it is plausible that the mechanisms of hypertrophic preconditioning may be far more complicated than the involvement S100A8/9, which needs to be clarified in future studies.

Ca^2+^ is essential for transcriptional activation during cardiac hypertrophy. Among the Ca^2+^-dependent signaling pathways implicated in cardiac hypertrophy, the activation of calcineurin and subsequent nuclear translocation of NFAT are particularly important.^[@R48],[@R49]^ As members of the S100 calcium-binding family of proteins, S100A8 and S100A9 are likely to exert their intracellular regulatory activities by interacting with specific targets in a Ca^2+^-dependent manner.^[@R50],[@R51]^ Using cultured cardiomyocytes, we showed that NE increased the expression of calcineurin and nuclear translocation of NFAT, whereas treatment with S100A8 and S100A9 prevented these changes, indicating that S100A8 and S100A9 attenuate cardiac hypertrophy by inhibiting the calcineurin/NFAT--signaling pathway.

It is likely that other factors induced after withdrawal or attenuation of hypertrophic stimulation may contribute to protection of the heart in addition to S100A8/A9. A clinical investigation has shown that periodic intravenous infusion (5 consecutive days every 6 weeks) of iloprost (a prostacyclin analog) protects against the onset or exacerbation of pulmonary artery hypertension and decreases the serum level of N-terminal pro B-type natriuretic peptide,^[@R52]^ effects similar to those of hypertrophic Pre. Because iloprost has a short half-life of 20 to 30 minutes, its pharmacological antihypertensive effect would not persist for as long as 6 weeks, suggesting that 5 days of treatment with iloprost induces the production of antihypertensive factors that prevent the development of pulmonary hypertension after its withdrawal. Similarly, several experimental studies have demonstrated that antihypertensive and organ protective effects can persist for some time after the discontinuation of antihypertensive therapy.^[@R53]--[@R55]^

Inhibition of the compensatory hypertrophy is traditionally believed to be detrimental for cardiac function. However substantial evidence from experimental studies, especially from gene-targeted animals, call into question the necessity of hypertrophic growth of the heart as a compensatory response to hemodynamic stress.^[@R56]^ In the present study, it is plausible to postulate that preconditioning stimuli (short-term TAC) per se should induce a compensatory hypertrophy and then inhibit the progression of hypertrophy (maybe pathological or decompensatory phase) in response to reimposition of hypertrophic stimuli.

In conclusion, this study provided the first evidence for the phenomenon of myocardial hypertrophy preconditioning. We demonstrated that preconditioning by prohypertrophic factors exerts an antihypertrophic effect and slows the progression of HF, indicating the existence of hypertrophic preconditioning. Suppression of the calcineurin/NFAT pathway by S100A8/A9 partially explains the cardiac protection of hypertrophic preconditioning.
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CLINICAL PERSPECTIVE {#s1}
====================

Pathological myocardial hypertrophy is detrimental and contributes to the eventual progression to heart failure. Although myocardial ischemic preconditioning is known to be cardioprotective and is now applicable in clinical practice, it is unknown whether a similar phenomenon for hypertrophic stress and myocardial hypertrophy/heart failure, which we termed myocardial hypertrophic preconditioning, exists. In this study, we demonstrated that preconditioning by prohypertrophic factors increases the resistance of the heart to subsequent hypertrophic stress and delays progression from hypertrophy to heart failure, indicating the existence of the hypertrophic preconditioning phenomenon. We further showed that the upregulation of S100A8/A9 following the removal of transient hypertrophic stimulus contributes to the antihypertrophic and anti--heart failure effect of hypertrophic preconditioning, at least in part by suppressing the calcineurin/nuclear factor of the activated T cells pathway. These findings suggest that the induction of hypertrophic preconditioning has the potential to become a new approach to providing cardioprotection for patients with pressure overload. There are clinical clues for the phenomenon of hypertrophic preconditioning. Physical exercise can induce physiological myocardial hypertrophy and also benefit patients with heart failure, whereas, in patients with transposition of the great vessels, ventricular retraining with an adjustable banding device may lead to better survival. Further study is warranted to optimize hypertrophic preconditioning for the clinical prevention and therapy of heart failure.
